Furthermore, tau-mediated transport deficits sensitize neurons to amyloid-beta toxicity: reducing tau levels in AD models alleviates Aβ-induced impairments in mitochondrial motility, highlighting a synergistic interplay between tau and Aβ in mitochondrial and synaptic pathology [113]. The gene discussed is MAPT; the disease is Alzheimer disease.